Based on the primary endpoint midazolam metabolic ratio, we observe a slight trend towards a weak increase in CYP3A4 activity in patients with rheumatoid arthritis after 3 weeks of anti-IL-6R therapy. The gene discussed is CYP3A4; the disease is rheumatoid arthritis.